Loading...
NPI 1124725817 · Deerfield Beach, FL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Prince Laboratories Limited Liability Company is a clinical medical laboratory provider located in Deerfield Beach, Florida. This profile covers 58 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Prince Laboratories Limited Liability Company |
| Address | 450 Fairway Dr Ste 104 |
| City | Deerfield Beach |
| State | FL |
| ZIP | 33441 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | February 13, 2023 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $4.6M |
| Medicaid | $1.2K |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
58 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81419 | The lab analyst performs the technical lab test on a specimen such as blood to conduct a genomic sequence analysis panel. The test evaluates the genetic sequences of at least the 24 genes listed in… | 300 | $2,400 | $715.2K |
| 81440 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least 100 mitochondrial genes encoded in the nucleus, including 19 specific… | 170 | $3,240 | $537.7K |
| 81443 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least 15 genes, such as the 20 gene examples listed in the code descriptor. The… | 170 | $2,390 | $396.1K |
| 81307 | The lab analyst performs the technical lab test on a specimen such as blood, to analyze the entire gene sequence for the partner and localizer of BRCA2 (PALB2) gene. | 480 | $660 | $316.9K |
| 81238 | The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene. | 490 | $590 | $287.5K |
| 81249 | The lab analyst performs the technical lab test to analyze known the full gene sequence of the glucose–6–phosphate dehydrogenase (G6PD) gene. | 490 | $590 | $286.4K |
| 81321 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the phosphatase and tensin homolog, or PTEN, gene. | 440 | $590 | $261.1K |
| 81223 | The lab analyst performs the technical lab test to analyze the entire gene sequence for cystic fibrosis transmembrane conductance regulator gene, also known as CFTR. | 500 | $490 | $243K |
| 81334 | The lab analyst performs the technical lab test to detect the presence of specific changes in the runt related transcription factor 1 (RUNX) gene for targeted sequence analysis, such as exons 3–8. | 500 | $320 | $159.9K |
| 81311 | The lab analyst performs the technical lab test to analyze variants in exon 2, such as codons 12 and 13, and exon 3, such as codon 61, for the neuroblastoma RAS viral, v–ras, oncogene homolog, also… | 380 | $290 | $108.8K |
Showing 1–10 of 58
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 58 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
58 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81440 | 3 | 10 | 170 | $3,240 | $658.4K |
| 81307 | 11 | 30 | 320 | $660 | $508.3K |
| 81443 | 4 | 10 | 170 | $2,400 | $481.7K |
| 81321 | 11 | 30 | 430 | $580 | $467.7K |
| 81238 | 10 | 20 | 330 | $590 | $440.3K |
| 81419 | 3 | 10 | 90 | $2,400 | $434.1K |
| 81162 | 13 | 20 | 100 | $1,780 | $403.3K |
| 81249 | 9 | 20 | 290 | $590 | $383.1K |
| 81223 | 9 | 20 | 340 | $490 | $329.3K |
| 81351 | 18 | 20 | 210 | $630 | $307.8K |
Showing 1–10 of 58
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81238 | The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene. | 10 | $50 | $590 |
| 81279 | The lab analyst performs the technical lab test on a specimen such as blood to analyze specific gene sequences of the JAK2 (Janus kinase 2) gene, such as exons 12 and 13, which may be associated with… | 10 | $10 | $180 |
| 81339 | The lab analyst performs the technical lab test on a specimen such as blood to analyze specific gene sequences of the MPL (MPL proto–oncogene, thrombopoietin receptor) gene, such as exon 10, which… | 10 | $10 | $180 |
| 81345 | The lab analyst performs the technical lab test to analyze targeted genes, such as the promotor region for the telomerase reverse transcriptase gene (TERT). | 10 | $10 | $180 |
| 81250 | The lab analyst performs the technical lab test to detect the presence of specific changes in the gene for glucose–6–phosphatase, catalytic subunit, also known as G6PC. | 10 | $1 | $60 |
How this provider's Medicaid billing volume and revenue compare to other Florida providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Florida median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81238 | The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene. | 11 | 10 | 60 | $30 | $4.9K |
| 81279 | The lab analyst performs the technical lab test on a specimen such as blood to analyze specific gene sequences of the JAK2 (Janus kinase 2) gene, such as exons 12 and 13, which may be associated with… | 12 | 10 | 70 | $20 | $3.9K |
| 81339 | The lab analyst performs the technical lab test on a specimen such as blood to analyze specific gene sequences of the MPL (MPL proto–oncogene, thrombopoietin receptor) gene, such as exon 10, which… | 7 | 10 | 50 | $10 | $3.7K |
| 81345 | The lab analyst performs the technical lab test to analyze targeted genes, such as the promotor region for the telomerase reverse transcriptase gene (TERT). | 9 | 10 | 80 | $10 | $3K |
| 81250 | The lab analyst performs the technical lab test to detect the presence of specific changes in the gene for glucose–6–phosphatase, catalytic subunit, also known as G6PC. | 6 | 10 | 90 | $10 | $1.6K |
Other providers in the same ZIP code as Prince Laboratories Limited Liability Company, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Butterfly Effects, LLC | FL | Early Intervention Provider Agency | $0 | $18.3M |
| Reliable Results Labs Inc | FL | Clinical Medical Laboratory | $11.6M | $6.7K |
| Total Renal Care Inc | FL | End-Stage Renal Disease (ESRD) Treatment Clinic/Center | $0 | $10.4M |
| Mark Mitchell | FL | Emergency Medicine Physician | $1.9M | $38.2K |
| David Van Roekel | FL | Diagnostic Radiology Physician | $94.3K | $0 |
| William Mazzei | FL | Family Medicine Physician | $68.2K | $0 |
| Laura Haughie | FL | Physical Therapist | $52.3K | $0 |
| Philip Zwiebel | FL | Anesthesiology Physician | $23.7K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.